CN1778318A - Compound injection from ice tablet and ginkgo leaf extract and its making method thereof - Google Patents
Compound injection from ice tablet and ginkgo leaf extract and its making method thereof Download PDFInfo
- Publication number
- CN1778318A CN1778318A CN 200410065335 CN200410065335A CN1778318A CN 1778318 A CN1778318 A CN 1778318A CN 200410065335 CN200410065335 CN 200410065335 CN 200410065335 A CN200410065335 A CN 200410065335A CN 1778318 A CN1778318 A CN 1778318A
- Authority
- CN
- China
- Prior art keywords
- injection
- borneolum syntheticum
- folium ginkgo
- group
- weight portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002347 injection Methods 0.000 title claims abstract description 48
- 239000007924 injection Substances 0.000 title claims abstract description 48
- 150000001875 compounds Chemical class 0.000 title claims description 28
- 238000000034 method Methods 0.000 title description 7
- 239000009429 Ginkgo biloba extract Substances 0.000 title 1
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 52
- 239000003814 drug Substances 0.000 claims abstract description 24
- 241000218628 Ginkgo Species 0.000 claims description 62
- 235000011201 Ginkgo Nutrition 0.000 claims description 62
- 235000008100 Ginkgo biloba Nutrition 0.000 claims description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 48
- 239000000284 extract Substances 0.000 claims description 44
- 239000008215 water for injection Substances 0.000 claims description 24
- 238000003756 stirring Methods 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000000243 solution Substances 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 18
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 239000007788 liquid Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 229940079593 drug Drugs 0.000 claims description 14
- 239000012528 membrane Substances 0.000 claims description 13
- 230000003204 osmotic effect Effects 0.000 claims description 13
- 238000000108 ultra-filtration Methods 0.000 claims description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 11
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical group OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 229930195725 Mannitol Natural products 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 239000000594 mannitol Substances 0.000 claims description 10
- 235000010355 mannitol Nutrition 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 8
- 230000001954 sterilising effect Effects 0.000 claims description 8
- 238000004659 sterilization and disinfection Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000001802 infusion Methods 0.000 claims description 6
- 239000004615 ingredient Substances 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Chinese gallotannin Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 4
- 238000005352 clarification Methods 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 230000004907 flux Effects 0.000 claims description 3
- 210000004907 gland Anatomy 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 11
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 9
- 206010008118 cerebral infarction Diseases 0.000 abstract description 5
- 201000006474 Brain Ischemia Diseases 0.000 abstract description 3
- 206010008120 Cerebral ischaemia Diseases 0.000 abstract description 3
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 2
- 244000194101 Ginkgo biloba Species 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 229910052709 silver Inorganic materials 0.000 description 24
- 239000004332 silver Substances 0.000 description 24
- 241000700159 Rattus Species 0.000 description 20
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 19
- 230000000694 effects Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 15
- 210000000582 semen Anatomy 0.000 description 13
- 230000002085 persistent effect Effects 0.000 description 7
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 6
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 5
- 108010003541 Platelet Activating Factor Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 206010067125 Liver injury Diseases 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- -1 transfusion Substances 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 230000000302 ischemic effect Effects 0.000 description 3
- 150000002596 lactones Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 2
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 206010061216 Infarction Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 2
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000439 acute liver injury Toxicity 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 125000002604 borneol group Chemical group 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 210000004720 cerebrum Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000009189 diving Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930182486 flavonoid glycoside Natural products 0.000 description 2
- 150000007955 flavonoid glycosides Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007574 infarction Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 229960000715 nimodipine Drugs 0.000 description 2
- 229940100243 oleanolic acid Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 241000218631 Coniferophyta Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical group C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 229940021171 curative drug Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 230000007866 hepatic necrosis Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007087 memory ability Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 210000003657 middle cerebral artery Anatomy 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 125000000955 oleanolic acid group Chemical group 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 239000008918 xingnaojing Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine in the form of injection for treating cardiovascular and cerebrovascular diseases such as cerebral infarction, cerebral ischemia, coronary heart disease, angina pectoris and myocardial infarction is proportionally prepared from borneol and gingko leaf through extracting their active components.
Description
Technical field
The present invention relates to a kind of compound injection of forming by a certain percentage by Borneolum Syntheticum and Folium Ginkgo extract and preparation method thereof.Belong to medical technical field.
Background technology
Cardiovascular and cerebrovascular disease is first killer of harm humans life and health, according to updated statistics, the whole world had 1,700 ten thousand people to die from cardiovascular disease in 2000, account for 1/3 of the total death toll of global a variety of causes, expect this numeral of the year two thousand twenty and will increase to 2,500 ten thousand, and wherein 80% all in developing country.
According to China's population analysis on cause of death in 1997, tumor held pride of place in the urban population cause of death, and cerebrovascular accounts for second, and both numerical value is bordering on equal; Respiratory system disease holds pride of place in the rural population cause of death, and cerebrovascular accounts for second.Ischemic cerebrovascular is all accounting for 70% in the cerebrovascular.Cardiovascular and cerebrovascular disease has quite high sickness rate and disability rate, can not be ignored.
Semen Ginkgo belongs to a kind of kind for only depositing a section one, have the title of gymnosperm " living fossil ".Mainly contain: blood circulation promoting, prevention cardiovascular and cerebrovascular disease, lifting memory, functions such as prevention senile dementia, antioxidation, the formation of prevention blood clot.At present, from Folium Ginkgo, isolated 30 activity chemistry compositions, but clinical medicinal main chemism composition still is total flavones and total lactone.Gingko leaf preparation is mainly used in treatment cardiovascular and cerebrovascular disease, neural mental disease, diseases of the five sense organs, respiratory system disease, urologic disease clinically with other cancer, to the protective effect of organ transplant rejection etc., and Semen Ginkgo is very low in mammiferous toxicity.
Borneolum Syntheticum has the refreshment of having one's ideas straightened out, the effect of clearing away heat to alleviate pain.Modern study shows, Borneolum Syntheticum not only self very permeable is crossed blood brain barrier, and the effect of performance consciousness-restoring and orifice-opening can also increase the blood-brain barrier permeability of other medicines, increases the curative effect of medicine to brain diseases.
Its distribution half-life of Borneolum Syntheticum intravenously administrable is 2.8 minutes, be distributed to histoorgan performance curative effect very soon, and the oral elimination half-life is 5.3 hours, illustrates that Borneolum Syntheticum absorbs slowly and bioavailability is low.Borneolum Syntheticum amount in minority injection such as XINGNAOJING ZHUSHEYE, QINKAILING ZHUSHEYE is also very low, is difficult to reach medicine effective concentration and affects the treatment.
Do not find as yet with the compound preparation of Folium Ginkgo extract and Borneolum Syntheticum compatibility separately, its correlational study document does not see that report is arranged yet, both have good therapeutical effect to the cardiovascular and cerebrovascular vessel acute illness, can bring into play synergism behind the compound recipe, cardiovascular and cerebrovascular vessel acute attack stage particularly, onset and reach desired therapeutic effect rapidly.
Summary of the invention
The object of the present invention is to provide a kind of compound injection of being made up of by a certain percentage Chinese medicine Borneolum Syntheticum and Folium Ginkgo extract, can be used for cardiovascular and cerebrovascular disease, it can overcome the shortcoming that the oral formulations absorption difference is waited a moment.Pharmacodynamic experiment proves that the Chinese medicine of forming with the effective site Folium Ginkgo extract and the Borneolum Syntheticum of Folium Ginkgo extract is used for the qi depression to blood stasis cardiovascular and cerebrovascular disease, and is evident in efficacy.This compound injection agent medicine shows that through toxicological experiment toxicity is minimum, and through the side's of tearing open research, these two medicines of writing out a prescription lump together adapted, obviously strengthens with any not only drug effect wherein than single, and has Attenuation.The present invention also provides the preparation method of above-mentioned compound injection.
The effective ingredient in Chinese compound injection that the present invention proposes, the compound injection of forming by a certain percentage by Chinese medicine Borneolum Syntheticum and Folium Ginkgo extract.
This effective ingredient in Chinese compound injection, its proper proportioning is: Borneolum Syntheticum: 1 part, Folium Ginkgo extract: 2-20 part.
This compound injection can be dosage forms such as liquid drugs injection, powder pin and transfusion.
This compound injection is in order to various cardiovascular and cerebrovascular diseases such as treatment ischemic brain injury, angina pectoris, myocardial ischemia.
The compatibility of this compound injection uses, major advantage is: Borneolum Syntheticum can increase the effective ingredient bioavailability in vivo of Semen Ginkgo, improve its curative effect, strengthen central action, Semen Ginkgo can be improved the dissolubility of Borneolum Syntheticum in water, Folium Ginkgo extract and the potentiation of Borneolum Syntheticum compatibility, this preparation is rapid-action, the curative effect height.
The preparation of Folium Ginkgo extract can be undertaken by following technology, the Folium Ginkgo of getting certain mass is with the finite concentration alcohol reflux, concentrating under reduced pressure, after the clarifier sedimentation, concentrating under reduced pressure is with the 50% left and right sides ethanol dried coarse powder of desilver Folium Pruni that boils again, adsorption resin column on the filtrate, at last pale yellow powder shape extract, contain flavonoid glycoside and Ginkgo total lactones and be not less than 24%, 6% respectively.
Borneolum Syntheticum is the commercially available prepared slices of Chinese crude drugs that meet the Chinese Pharmacopoeia standard.
The invention allows for above-mentioned composition, its liquid drugs injection, transfusion, powder injection formulation prepare as follows:
Get Borneolum Syntheticum 1 weight portion, fine ground, add 30-70 weight portion glycerol heated and stirred and make dissolving fully, standby.Get Folium Ginkgo extract 2-20 weight portion, add an amount of water for injection dissolving, the glycerite of above-mentioned Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir, the osmotic pressure regulator of making milliosmolaritys such as need adding to when infusing makes dissolving, this osmotic pressure regulator is at least a in mannitol, sodium chloride or the glucose, is diluted to certain volume with proper amount of water for injection, mixing.Medicinal liquid is the ultrafilter membrane ultrafiltration of 10000～30000 molecular weight through flux, and embedding becomes injection or transfusion, and sterilization promptly gets injection, primary infusion preparation.
Get Borneolum Syntheticum 1 weight portion, fine ground, add an amount of anhydrous alcohol solution after, slowly add with 8-15 weight portion HP-and be made in the saturated aqueous solution, insulation 40-60., stirring or the ultrasonic solution that makes are clarified.Other gets Folium Ginkgo extract 2-20 weight portion, adds an amount of water for injection dissolving.The HP-enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir, the osmotic pressure regulator of making milliosmolaritys such as need adding to when infusing makes dissolving, this osmotic pressure regulator is at least a in mannitol, sodium chloride or the glucose, be diluted to certain volume with proper amount of water for injection, mixing.The ultrafilter membrane ultrafiltration of medicinal liquid via hole diameter 30000～100000 molecular weight, embedding becomes injection or primary infusion, and sterilization promptly gets injection, primary infusion preparation.
Get Borneolum Syntheticum 1 weight portion, fine ground, after adding an amount of anhydrous alcohol solution, slowly add with 8-15 weight portion HP-and be made in the saturated aqueous solution, be incubated 40-60 ℃, stirring or the ultrasonic solution that makes are clarified, other gets Folium Ginkgo extract 2-20 weight portion, adds the dissolving of an amount of water for injection, and the HP-enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir, add an amount of forming agent again and make dissolving, this forming agent is a mannitol, at least a in HP-or the glucose is diluted to certain volume with proper amount of water for injection, stir, the ultrafilter membrane ultrafiltration of medicinal liquid via hole diameter 30000～100000 molecular weight, ultrafiltrate packing, lyophilizing, gland promptly gets the powder pin.
Pharmacodynamic experiment of the present invention
One, to the effect of mice ischemia-reperfusion learning memory disorder model
Get 6 groups of male SD mices and be divided into sham operated rats, model group, TANSHINONES positive drug control group and compound recipe silver ice injection group, Folium Ginkgo extract group, Borneolum Syntheticum group, every group of 10 animals at random, irritate stomach every day 1 time, blank group and model group such as give at the capacity normal saline, continuous 15 days, 1h after the last administration caused the imperfection bilateral bloodstream blocking of mice according to method, cause cerebrum ischemia, behind the 5min, remove vascular ligation, make common carotid artery reply blood flow and pour into again.Use the multi-functional avoidance condition of JZZ94 instrument next day, carry out the passive learning memory training, errors number (N), stimulation time (Ts) and platform retention (T) that the record mice jumps off electric grid from diving tower with the diving tower method.Test again after 24 hours.The results are shown in Table 1.
The influence (X ± S n=10) of table 1 pair mouse brain ischemia-reperfusion learning and memory of little mouse
| Group | Dosage every day (mg/kg) | Plateau (s) | Stimulation time (s) | Mistake number (N) |
| Blank model group silver ice group (1: 1) silver-colored ice group (1: 5) silver-colored ice group (1: 10) ginkgo group borneol group tanshinone group | 10 10 10 8 2 15 | 296.1±2.0 290.2±5.4 ## 296.8±2.1 ** 297.7±2.1 * 295.6±22 ** 294.3±1.6 * 290.3±3.1 294.1±1.8 * | 0.4±0.66 4.3±2.6 ## 1.1±0.5 ** 1.4±0.7 ** 09±0.7 ** 2.1±1.1 * 42±2.4 1.8±0.5 * | 1.8±1.8 3.5±1.9 0.8±0.7 * 0.7±0.6 * 1.3±1.1 * 2.5±1.5 3.0±1.7 1.6±2.0 |
Annotate: compare with the blank group,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Result of the test shows that model group and sham operated rats relatively have significant difference (P＜0.01), shows mice modeling success.Compound recipe silver ice injection and model group relatively have significant difference (P＜0.01), show that this injection increases significantly to the memory ability of mice.Compare with the Folium Ginkgo extract group (P＜0.05), the compound injection group has better effect to the memory of mice, and the Borneolum Syntheticum in the compound recipe sees through blood brain barrier at it, promotes drug absorption, promoting the medicine bulk concentration to increase the aspect has better action, has also shown the reasonability of this compound recipe.
Two, the influence of the persistent period of panting behind the mice broken end is tested
Get 50 of Bal/BC mices, be divided into blank group, nimodipine positive drug control group and silver ice injection use compound group, Borneolum Syntheticum group, Folium Ginkgo extract group at random, every group of 10 animals.Wherein, silver ice dosage is according to document conversion animals administer dosage, and the nimodipine group is according to human body consumption conversion mice dosage.Blank group normal saline is irritated stomach, and all the other are respectively organized relative medicine and irritate stomach, and 1 time/d, continuous 7d.15min after the last administration breaks end under the mice basal part of the ear fast, and record begins to pant the persistent period as broken end to its time that stops of panting for the last time from broken end.The results are shown in Table 2.
Influence (the n=10 of X ± S) of persistent period pants behind the table 2 pair mice broken end
| Group | Dosage every day (mg/kg) | (s) breathes the persistent period |
| Blank group silver ice group Semen Ginkgo group Borneolum Syntheticum group nimodipine group | 10 8 2 10 | 20.1±1.37 24.5±1.52 ** 20.35±1.43 22.7±1.28 * 23.45±1.69 |
Annotate: compare with the blank group,
*P＜0.05,
*P＜0.01.
Experimental result shows, ig compound recipe silver ice, single Borneolum Syntheticum are panted the persistent period after all obviously prolonging the mice broken end, with the blank group relatively, be significant difference (
*P＜0.05,
*P＜0.01), it is not obvious that ig single Folium Ginkgo extract prolongs the persistent period of panting after mice breaks end, and compares there was no significant difference with the blank group.But compound recipe silver ice injection group is more more remarkable than the effect that Borneolum Syntheticum group and Folium Ginkgo extract group prolong the persistent period of panting behind the mice broken end, and the prompting compound injection can significantly improve cerebral ischemia treatment of diseases effect, and is more more superior than the therapeutic effect of single medicine.
Three, intraluminal middle cerebral artery occlusion in rats is caused the effect of cerebral ischaemia
Get 6 groups of male SD rats and be divided into sham operated rats, cerebral ischemic model group, nimodipine positive drug control group and compound recipe silver ice injection group, Folium Ginkgo extract group, Borneolum Syntheticum group, every group of 10 animals at random.Cause cortex of cerebral hemispheres and the basal nuclei ischemia injury model of rat according to blocking-up rat medium-sized artery (MCAO) method.Each organizes intravenous injection once, and administration is after 30 minutes, and each Mus is with 10% chloral hydrate anesthesia (300mg/kg, i β), undergo surgery by literature method, postoperative 24 hours broken end is got brain, dyed after, take out respectively and be normal cerebral tissue rosy and be linen blocking tissue, weigh,, obtain the percentage ratio that the infarct area accounts for the hemisphere gross area then according to the weight area method, t method of inspection and model group are carried out significance test relatively between i.e. infraction rate, and employing group.The results are shown in Table 3.
The influence of the table 3 pair rat cerebral infarction scope (n=10 of X ± S)
| Group | Dosage (mg/kg) | Number of animals (n) | Infarct size/brain sections the gross area (%, X ± S) |
| Sham operated rats model group silver ice group Semen Ginkgo group Borneolum Syntheticum group nimodipine group | 10 8 2 2 | 10 10 10 10 10 10 | 0 11.5±4.1 ## 8.1±4.0 ** 8.9±4.4 * 10.6±5.7 8.0±4.1 * |
Annotate: compare with sham operated rats,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Result of the test is learned by statistics and is shown, model group has been compared significant difference with sham operated rats, shows rat MCAO modeling success.Compare with model group; compound recipe silver ice injection group, Folium Ginkgo extract group all can reduce animal brain cerebral infarction rate; but compound recipe silver ice injection group has been compared significant difference (P＜0.01) with it; its protective effect to middle cerebral artery blocking-up (MCAO) rat is better than Semen Ginkgo group and nimodipine group (P＜0.05), shows the superiority of silver ice compound recipe thus.
Four, to the effect of rat acute liver injury model
Extracting male Wistar rat is divided at random: matched group, model group, basic, normal, high three the dosage groups of silver ice preparation, Folium Ginkgo extract group, Borneolum Syntheticum group and oleanolic acid positive drug control group, 10 every group.D-Gal amine (D-GalN) causes the rat acute liver injury model. give curative drug silver ice injection, Semen Ginkgo and positive drug placebo (oleanolic acid), 1 time/d, be total to 8d, the 7th day morning, give D-GalN modeling, the 8th day, broken end was got blood behind the last administration 1h, measure rat blood serum platelet activating factor (PAF), alanine aminotransferase (ALT), malonaldehyde (MDA), and light microscopic is observed the hepatic pathology variation down. the results are shown in Table 4.Table 5.
Table 4 is respectively organized the situation of change of rat blood serum PAF, ALT, MDA
| The group agent | Amount (mg/kg) | PAF(μg/L) | ALT(U/L) | MDA(nmol/L) |
| Normal group model group silver ice group (1: 1) silver-colored ice group (1: 5) silver-colored ice group (1: 10) ginkgo group borneol group oleanolic acid group | 10 10 10 8 2 60 | 1.09±0.18 4.6±0.33 ## 2.74±0.28 ** 2.65±0.22 ** 2.03±0.20 ** 3.12±0.27 ** 4.58±0.33 4.53±0.45 ** | 55.8±6.38 1092.7±88.50 ## 498±73.03 ** 501.7±45.04 ** 350.6±66.77 ** 521.3±60.1 ** 1089.8±86.3 508.8±58.91 ** | 5.86±2.70 16.43±3.78 ## 9.37±2.47 ** 8.62±2.33 ** 5.39±2.27 ** 7.47±2.41 ** 16.34±3.69 8.78±2.98 ** |
Annotate: compare with sham operated rats,
##P＜0.01; Compare with model group,
*P＜0.05,
*P＜0.01.
Result of the test shows that silver ice injection and Semen Ginkgo extrac group all have the good protective effect to acute liver damage, but compare with Semen Ginkgo, and the Borneolum Syntheticum in the silver ice has significant promotion to Semen Ginkgo extrac and absorbs, and improves bulk concentration, increases the superiority of curative effect.
The D-GalN that influences to pathological change brings out the rats'liver damage model, because of its pathological change is widely used to human virus's hepatitis is similar.This test pathological observation shows: hepatocyte bulk or inferior massive necrosis, and lobules of liver and hepatocyte disappear, and there were significant differences for hepatic pathology credit level and normal group (P＜0.01).Each dosage group blood-serum P AF of Semen Ginkgo, ALT, MDA and positive controls ALT, MDA then all are starkly lower than model group, hepatic necrosis obviously alleviates, and scope is dwindled, and visible lobules of liver structure, wherein preferable with silver ice dosage group curative effect especially, other each treatment group effect no significant differences.Conclusion: silver ice injection has protective effect to rat acute hepatic injury due to the D-GalN; its mechanism may be by removing oxygen-derived free radicals, antagonism PAF; improve that liver microcirculation realizes; Borneolum Syntheticum can significantly increase Semen Ginkgo effective ingredient concentration in vivo; improve its bioavailability, be expected to one of active drug that becomes the acute Severe Viral Hepatitis of clinical treatment.
Specific embodiment
Embodiment 1: the preparation of Folium Ginkgo extract
The Folium Ginkgo of getting certain mass is with 65% alcohol reflux, concentrating under reduced pressure, after the sedimentation of ZTC clarifier, concentrating under reduced pressure is with the 50% ethanol dried coarse powder of desilver Folium Pruni that boils again, last 724 adsorption resin columns of filtrate, at last pale yellow powder shape extract, contain flavonoid glycoside and Ginkgo total lactones is respectively 26%, 10.6%.
Embodiment 2: the preparation [] of silver ice injection
Get Borneolum Syntheticum (artificial or natural) 20g, fine ground, add 1000ml glycerol heated and stirred and make dissolving fully.Get Folium Ginkgo extract 2g and add the dissolving of 2-4L water for injection.The glycerite of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, and the limit edged stirs to clarify, and is diluted to 10L with water for injection.The medicinal liquid via hole diameter is the ultrafilter membrane ultrafiltration of 10000 molecular weight, embedding, and 10ml/ props up, and sterilization promptly gets injection.
Embodiment 3: the preparation [two] of silver ice injection
Get Borneolum Syntheticum (artificial or natural) 20g, fine ground, add an amount of anhydrous alcohol solution after, slowly add with the 600g HP-and be made in the saturated aqueous solution, be incubated 40-60 ℃, stir or ultrasonicly make the solution clarification.Other gets Folium Ginkgo extract 4g, adds an amount of water for injection dissolving.The HP-enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir, the osmotic pressure regulator of making milliosmolaritys such as need adding to when infusing makes dissolving, this osmotic pressure regulator is at least a in mannitol, sodium chloride or the glucose, be diluted to 20L with water for injection, mixing.The ultrafilter membrane ultrafiltration of medicinal liquid via hole diameter 30000～100000 molecular weight, embedding, 10ml/ props up, and sterilization promptly gets injection.
Embodiment 4: the preparation [] of silver ice transfusion
Get Borneolum Syntheticum (artificial or natural) 20g, fine ground, add 2400ml glycerol heated and stirred and make dissolving fully.Get Folium Ginkgo extract 2g and add the dissolving of 2-4L water for injection.The glycerite of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, the limit edged stirs, and the osmotic pressure regulator of milliosmolarity such as adds to, and this isotonic agent is at least a in mannitol, sodium chloride or the glucose, and be diluted to 100L or 250L with water for injection, stir.The medicinal liquid via hole diameter is the ultrafilter membrane ultrafiltration of 30000 molecular weight, and it is an amount of to replenish water for injection, is distributed into 100ml or 250ml/ bottle, irritates lid, and sterilization promptly gets and infuses.
Embodiment 5: the preparation [two] of silver ice transfusion
Get Borneolum Syntheticum (artificial or natural) 20g, fine ground, add an amount of anhydrous alcohol solution after, slowly add with the 200g HP-and be made in the saturated aqueous solution, be incubated 40-60 ℃, stir or ultrasonicly make the solution clarification.Other gets Folium Ginkgo extract 4g, adds an amount of water for injection dissolving.The HP-enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir, the osmotic pressure regulator of making milliosmolaritys such as need adding to when infusing makes dissolving, this osmotic pressure regulator is at least a in mannitol, sodium chloride or the glucose, and be diluted to 100L or 250L with water for injection, stir.The medicinal liquid via hole diameter is the ultrafilter membrane ultrafiltration of 30000 molecular weight, and it is an amount of to replenish water for injection, is distributed into 100ml or 250ml/ bottle, irritates lid, and sterilization promptly gets and infuses.
Embodiment 6: the preparation of silver-colored freezing dry powder injection
Get Borneolum Syntheticum (artificial or natural) 20g, fine ground, add the 40ml anhydrous alcohol solution, standby.Other gets HP-240g, is made into drink and solution, adds Borneolum Syntheticum ethanol liquid while stirring, and stirring or ultrasonic enclose get settled solution.Get Folium Ginkgo extract 4g, add an amount of water for injection dissolving.The hydroxypropyl enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, and the limit edged stirs to clarify, and is diluted to 50L with water for injection, dissolving.Medicinal liquid is the ultrafilter membrane ultrafiltration of 10000 molecular weight through flux, packing, and every bottle of 5ml, lyophilizing, gland, label promptly gets the powder pin, totally 10000 bottles.
Claims (5)
1, a kind of effective ingredient in Chinese compound injection that is used for the treatment of cardio-cerebralvascular diseases is characterized in that being made up according to a certain ratio by Borneolum Syntheticum and Folium Ginkgo extract and makes.
2, according to the preparation method of the described effective ingredient in Chinese compound injection of claim 1, it is characterized by:
One; get Borneolum Syntheticum 1 weight portion; fine ground; add 30-70 weight portion glycerol heated and stirred and make fully dissolving; be standby; as to get Folium Ginkgo extract 2-20 weight portion; add an amount of water for injection dissolving, the glycerite of above-mentioned Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir; the osmotic pressure regulator that milliosmolarity such as need add to when making transfusion makes dissolving; this osmotic pressure regulator is a mannitol; at least a in sodium chloride or the glucose, be diluted to certain volume with proper amount of water for injection, mixing; medicinal liquid is the ultrafilter membrane ultrafiltration of 10000～30000 molecular weight through flux; embedding becomes injection or transfusion, sterilization promptly gets liquid drugs injection; infusion preparation.
Two; get Borneolum Syntheticum 1 weight portion; fine ground; after adding an amount of anhydrous alcohol solution; slowly add with 8-15 weight portion HP-and be made in the saturated aqueous solution; be incubated 40-60 ℃; stir or ultrasonicly make the solution clarification; other gets Folium Ginkgo extract 2-20 weight portion; add an amount of water for injection dissolving, the HP-enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract, stir; the osmotic pressure regulator that milliosmolarity such as need add to when making transfusion makes dissolving; this osmotic pressure regulator is a mannitol; at least a in sodium chloride or the glucose, be diluted to certain volume with proper amount of water for injection, mixing; the ultrafilter membrane ultrafiltration of medicinal liquid via hole diameter 30000～100000 molecular weight; embedding becomes injection or primary infusion, sterilization promptly gets injection; the primary infusion preparation.
Three; get Borneolum Syntheticum 1 weight portion; fine ground; after adding an amount of anhydrous alcohol solution; slowly add with 8-15 weight portion HP-and be made in the saturated aqueous solution; be incubated 40-60 ℃; stir or ultrasonicly make the solution clarification; other gets Folium Ginkgo extract 2-20 weight portion, adds an amount of water for injection dissolving, the HP-enclose solution of Borneolum Syntheticum is slowly added in the aqueous solution of Folium Ginkgo extract; stir; add an amount of forming agent again and make dissolving, this forming agent is a mannitol; at least a in HP-or the glucose, be diluted to certain volume with proper amount of water for injection; stir; the ultrafilter membrane ultrafiltration of medicinal liquid via hole diameter 30000～100000 molecular weight, ultrafiltrate packing, lyophilizing; gland promptly get the powder pin.
3,, it is characterized in that the ultrafilter membrane ultrafiltration of medicinal liquid with 10000～30000 molecular weight according to the liquid drugs injection of claim 2 and the preparation method of transfusion.
4, according to the preparation method of the powder ampoule agent for injection of claim 2, it is characterized in that the ultrafilter membrane ultrafiltration of filtrate with 30000～100000 molecular weight.
5, according to the preparation method of the injection of claim 2, what it is characterized in that adjuvant can be in mannitol, sodium chloride or the glucose is at least a.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100653358A CN100346797C (en) | 2004-11-26 | 2004-11-26 | Compound injection from ice tablet and ginkgo leaf extract and its making method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100653358A CN100346797C (en) | 2004-11-26 | 2004-11-26 | Compound injection from ice tablet and ginkgo leaf extract and its making method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1778318A true CN1778318A (en) | 2006-05-31 |
| CN100346797C CN100346797C (en) | 2007-11-07 |
Family
ID=36768855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100653358A Expired - Fee Related CN100346797C (en) | 2004-11-26 | 2004-11-26 | Compound injection from ice tablet and ginkgo leaf extract and its making method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100346797C (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101628018B (en) * | 2009-08-14 | 2011-05-18 | 陕西科技大学 | Method for preparing enriched-flavone low-toxicity gingko leaves |
| CN103877130A (en) * | 2013-09-17 | 2014-06-25 | 狄留庆 | Chinese medicinal composition for treating ischemic cerebral paralysis, application thereof to preparation of oral preparation and preparation of Chinese medicinal composition |
| CN111166774A (en) * | 2019-12-13 | 2020-05-19 | 南京中医药大学翰林学院 | Composition for preventing and treating cerebral ischemia diseases and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1296060C (en) * | 2002-05-14 | 2007-01-24 | 天津帝士力投资控股集团有限公司 | Compound ginkgo leaf reparation and its making method |
-
2004
- 2004-11-26 CN CNB2004100653358A patent/CN100346797C/en not_active Expired - Fee Related
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101628018B (en) * | 2009-08-14 | 2011-05-18 | 陕西科技大学 | Method for preparing enriched-flavone low-toxicity gingko leaves |
| CN103877130A (en) * | 2013-09-17 | 2014-06-25 | 狄留庆 | Chinese medicinal composition for treating ischemic cerebral paralysis, application thereof to preparation of oral preparation and preparation of Chinese medicinal composition |
| CN111166774A (en) * | 2019-12-13 | 2020-05-19 | 南京中医药大学翰林学院 | Composition for preventing and treating cerebral ischemia diseases and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100346797C (en) | 2007-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2016107579A1 (en) | Preparation and application of flavonol as brain-targeting synergist | |
| CN1943618A (en) | Red sage root effective part standard extract and its preparing method and use | |
| CN102895278B (en) | Application of arctinin and arctigenin in resisting parkinsonism | |
| CN100346797C (en) | Compound injection from ice tablet and ginkgo leaf extract and its making method thereof | |
| CN110025664B (en) | Pharmaceutical composition for preventing and treating cerebral infarction and/or vascular dementia and application thereof | |
| CN101181285A (en) | Application of astragaloside IV in the preparation of medicament for curing nervus retrogression disease | |
| CN1060344C (en) | Shumaining preparation for curing ischemic angiocardiopathy or cerebrovascular disease | |
| WO2009062374A1 (en) | The pharmaceutical use of liquiritigenin for preparing medicine for treating neurodegenerative diseases | |
| CN101507747B (en) | Preparation method of astragalus total-saponin sodium chloride injector | |
| CN100496506C (en) | Puerarin injection | |
| CN101327215B (en) | Medicament composition containing protoberberine type alkaloids | |
| CN100417388C (en) | Compound injection preparation containing ligustrazine and breviscapine and its preparation method | |
| CN1663600B (en) | Compound preparation composed of ginkgo leaf extracts and medicines promoting cerebral metabolism and its application | |
| CN1135979C (en) | Application of sophocarpine in preparation of medicine for curing coxsackievirus B myocarditis and its preparation method | |
| CN102716231B (en) | A kind of Chinese medicine composition and application thereof for the treatment of brain injury and cerebral edema | |
| CN1275590C (en) | Dispersion tablet containing ginkgo leaf extract | |
| CN100417387C (en) | Compound injection formulation compose dof borneol and pseudo-ginseng total saponin and its preparing method | |
| CN100348216C (en) | Compound injection from ice tablet and Danshen Root extract and its preparation thereof | |
| CN100400054C (en) | Compound injection from Chunxiongqin and Sanchi general saponin and its preparation | |
| CN100363010C (en) | Compound injection composed of borneol and wilsonii extract and its preparing method | |
| RU2789693C1 (en) | Agent for reduction in pathomorphological manifestations of post-toxic liver cirrhosis and its complications | |
| CN1781490A (en) | Compound injection composed of borneol and erigeron breviscapus and its preparing method | |
| CN102228427A (en) | Vitexin glucoside injection and preparation method thereof | |
| CN1785246A (en) | Compounding injection prepn. contg. extractives of red-rooted salvia and total notogisennoside and its prepn. method | |
| CN101152198A (en) | Nasal cavity administration preparation for treating diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Qin Yinlin Document name: Notification of registration procedures and notice of patent for invention |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. Assignor: Qin Yinlin Contract fulfillment period: 2008.10.10 to 2018.11.6 Contract record no.: 2008320000982 Denomination of invention: Compound injection from ice tablet and ginkgo leaf extract and its making method thereof Granted publication date: 20071107 License type: Exclusive license Record date: 20081015 |
|
| LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2008.10.10 TO 2018.11.6; CHANGE OF CONTRACT Name of requester: JIANGSU KEFEIPINGMEDICINE CO., LTD. Effective date: 20081015 |
|
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU CAREFREE PHARMACEUTICAL CO., LTD. Effective date: 20120817 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20120817 Address after: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee after: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. Address before: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee before: Qin Yinlin |
|
| C56 | Change in the name or address of the patentee |
Owner name: JIANGSU CAREFREE MEDICINE CO., LTD. Free format text: FORMER NAME: JIANGSU CAREFREE PHARMACEUTICAL CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee after: JIANGSU CAREPHAR PHARMACEUTICAL Co.,Ltd. Address before: 210016 Jiangsu Province, Nanjing city Zhongshan Road No. 323, 2 (former banshanyuan No. 12 Building 1 layer 1) Patentee before: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. |
|
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: JIANGSU CAREFREE PHARMACEUTICAL Co.,Ltd. Assignor: Qin Yinlin Contract record no.: 2008320000982 Date of cancellation: 20160613 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20071107 Termination date: 20211126 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |